ASAM Member Survey Results

797 views
741 views

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
797
On SlideShare
0
From Embeds
0
Number of Embeds
170
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

ASAM Member Survey Results

  1. 1.  91.7% of respondents (343 out of 374) have a DEA waiver to prescribe buprenorphine for at least 30 patients  73.3% are waivered to treat 100 patients  43.8 % of respondents indicated they have demand for buprenorphine treatment that exceeds the 100 patient limit
  2. 2. 6.3% 30.4% 10.1% 7.4% 15.5% 30.4% 0% 5% 10% 15% 20% 25% 30% 35% More than 100 81-100 61-80 41-60 21-40 Fewer than 20 The Number Patients per Month for whom Respondents Currently Prescribe Buprenorphine for theTreatment of Opioid Dependence
  3. 3. 2.8% 62.8% 8.9% 10.0% 23.1% 18.3% 0% 10% 20% 30% 40% 50% 60% 70% Other* None of the above All of the above CertifiedAddictions Registered Nurses (CARN) Nurse Practitioners Physicians'Assistants Percent of Respondents Who FeelThis Group Should be Allowed to Apply for and Obtain a Waiver to Prescribe Buprenorphine for theTreatment of Opioid Addiction *Other comments include: lifting 100 patient limit for ABAM certified physicians, requiring supervision for above groups to prescribe.
  4. 4.  19.8% of respondents order or prescribe medications for the treatment of opioid dependence in/from a federally-approved OTP  79.5% of these order methadone  57.3% order or prescribe buprenorphine  Most respondents indicated that states impose requirements – such as time in treatment or compliance with diversion control programs – in order for patients to gain take-home privileges for buprenorphine
  5. 5.  38.7% of respondents prescribe extended release naltrexone for opioid dependent patients  The vast majority of patients (62.2%) receive their injection in a private office setting
  6. 6. 15.0% 8.3% 10.5% 66.2% 0% 10% 20% 30% 40% 50% 60% 70% More than 15 11-15 6-10 1-5 The Number of Patients for whom Respondents Currently Prescribe Extended Release Naltrexone
  7. 7.  55.4% of respondents prescribe oral naltrexone for opioid dependent patients

×